Revolution Medicines (RVMD) director receives new stock and option grants

Rhea-AI Filing Summary

Revolution Medicines director Frank Clyburn reported receiving equity awards in the form of common stock and stock options. He was granted 1,191 shares of Common Stock, increasing his direct holdings to 10,929 shares, and a separate grant of 3,127 Stock Options (Right to Buy) with a $162.99 exercise price, each option for one share of common stock.

The option grant will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next annual meeting following the grant date, as long as he remains a Service Provider under the company’s 2020 Plan through that vesting date. The filing also notes that his holdings include 4,080 restricted stock units, which typically convert into shares over time.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Clyburn Frank

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,127	$0.00	--
Grant/Award	Common Stock	1,191	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 3,127 shares (Direct, null); Common Stock — 10,929 shares (Direct, null)

Footnotes (1)

1. Includes 4,080 restricted stock units. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Key Figures

Common stock award: 1,191 shares Director holdings after award: 10,929 shares Stock options granted: 3,127 options +3 more

6 metrics

Common stock award 1,191 shares Grant of Common Stock on June 18, 2026

Director holdings after award 10,929 shares Total direct Common Stock holdings following transactions

Stock options granted 3,127 options Stock Option (Right to Buy) award on June 18, 2026

Option exercise price $162.99 per share Conversion or exercise price of stock options

Option expiration June 18, 2036 Expiration date of Stock Option (Right to Buy)

Restricted stock units included 4,080 RSUs RSUs included within reported holdings

Key Terms

restricted stock units, Stock Option (Right to Buy, exercise price, Service Provider, +1 more

5 terms

restricted stock units financial

"Includes 4,080 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy financial

"Stock Option (Right to Buy) with underlying Common Stock"

exercise price financial

"conversion_or_exercise_price: "162.9900" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Service Provider financial

"subject to the Reporting Person remaining a Service Provider"

2020 Plan financial

"as defined in the 2020 Plan through the vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:44 PM Accepted by SEC EDGAR 06/23/2026 - 05:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clyburn Frank

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DR

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		A		1,191	A	$0	10,929(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$162.99	06/18/2026		A		3,127		(2)	06/18/2036	Common Stock	3,127	$0	3,127	D

Explanation of Responses:

1. Includes 4,080 restricted stock units.

2. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

	/s/ Jack Anders, as Attorney-in-fact for Frank Clyburn	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did RVMD director Frank Clyburn report?

Frank Clyburn reported receiving 1,191 shares of Common Stock and 3,127 Stock Options (Right to Buy). These are equity awards, not open-market trades, and increase his direct position in Revolution Medicines.

How many Revolution Medicines shares does Frank Clyburn hold after this Form 4?

After the reported awards, Frank Clyburn directly holds 10,929 Revolution Medicines shares. This total includes 4,080 restricted stock units, which generally represent shares that may settle in stock over time, subject to vesting conditions.

What are the terms of Frank Clyburn’s new RVMD stock options?

Clyburn received 3,127 Stock Options with a $162.99 exercise price per share, expiring on June 18, 2036. Each option is exercisable for one share of Revolution Medicines common stock, following the vesting schedule described in the filing.

When do Frank Clyburn’s Revolution Medicines stock options vest?

The options vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the annual meeting following the grant date, provided he remains a Service Provider under the company’s 2020 Plan through that vesting date.

Are Frank Clyburn’s RVMD awards open-market purchases or compensation grants?

Both transactions are coded as A, indicating grants or awards. The common shares and options were granted at a reported price of $0.00 per share, reflecting equity compensation rather than open-market buying or selling of Revolution Medicines stock.